Lineage Cell Therapeutics KOL Event

Virtual, November 17, 2020

Lineage Cell Therapeutics, Inc.: OpRegen® - A Therapeutic Expert Review of Phase 1/2a Clinical Study Interim Results for the Treatment of Dry-AMD

Tuesday, November 17, 2020 @ 4:00pm ET / 1:00pm PT

Please join us for a call with therapeutic area expert Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine, to review updated interim results from Lineage’s Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD).  In its ongoing Phase 1/2a clinical study, Lineage has observed benefit in some patients, including increases in Best Corrected Visual Acuity, reduction in the growth of geographic atrophy, increases in reading speed and retinal restoration.

Therapeutic Area Expert: Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine.

In collaboration with the other Retinal Surgeons at CEI, Dr. Riemann is a principal investigator or co-investigator for many phase two and phase three FDA trials. Dr. Riemann specializes in medical and surgical vitreoretinal diseases including diabetic retinopathy, macular degeneration, retinal detachment, retinopathy of prematurity, vascular diseases of the retina, uveitis, histoplasmosis, complications of anterior segment surgery, endoscopic posterior segment surgery, and ocular trauma. Dr. Riemann is a member of the American Society of Retina Specialists, American Academy of Ophthalmology, Ohio State Medical Association, Cincinnati Academy of Medicine, Cincinnati Ophthalmology Society, and the Association for Research in Vision and Ophthalmology. His original research in the fields of Ophthalmology, Cardiology, and Endocrinology has been published in international peer reviewed scientific journals and has been presented at national scientific meetings.  He has several patents for innovative surgical technologies and enjoys sharing his passion for the blend of engineering and medicine.

Materials

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Lineage Cell Therapeutics [LCTX] US$199 MM MCap
Cell ther­a­py com­pany with 3 cl­ni­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]

Event Contact

Gitanjali Jain Ogawa
Solebury Trout